Prolonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms
Annals of Hematology · 10.08.2026 · 105 (12)
DOI: 10.1007/s00277-026-07233-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 10.08.2026. Verfasst von Ermelinda Longo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, AOU Policlinico "Rodolico - S. Marco", University of Catania, Catania, Italy. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Fusion Proteins, bcr-abl, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chronic-phase chronic myeloid leukemia (CP-CML) is currently treated with tyrosine kinase inhibitors (TKIs), and the early achievement of cytogenetic and molecular milestones is strongly associated with improved clinical outcomes. Here, we describe the case of a 55-year-old woman diagnosed with CP-CML in 2002 who received sequential TKI therapy for more than 20 years. Despite continuous treatment, she never achieved a complete cytogenetic response (CCyR) or a major molecular response (MMR), and the BCR::ABL1IS transcript levels remained above 10% for most of the disease course. At diagnosis, she presented with high-risk features, including p190 BCR::ABL1 transcript expression, and exhibited multiple mutations, but not driver ones, over time. Nevertheless, along with several TKIs treatments, she maintained a stable chronic-phase disease with sustained hematologic control and preserved a good quality of life throughout long-term follow-up. This case highlights the biological heterogeneity of CML, the timing and trajectory of BCR::ABL1-driven disease, the importance of patient-centered outcomes and the role of TKI therapy in maintaining durable hematologic remission and long-term disease control, even in the absence of optimal molecular milestones.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, AOU Policlinico "Rodolico - S. Marco", University of Catania, Catania, Italy.
- Department of Clinical and Experimental Medicine, University of Catania, Catania, 95123, Italy.
- Center of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", Catania, 95123, Italy.
- Provincial Health Agency of Ragusa, Ragusa, RG, Italy.
- Department of General Surgery and Medical-Surgical Specialties, University of Catania, Catania, 95123, Italy.
- Hematology Section, AOU Policlinico "G. Martino", University of Messina, via Consolare Valeria 1, Messina, 98124, Italy.
Zitieren
APA
Longo, E., Markovic, U., Stella, S., Antolino, A., Massimino, M., Fazio, M., Di Raimondo, F., Allegra, A., & Stagno, F. (2026). Prolonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms. Annals of Hematology, 105(12). https://doi.org/10.1007/s00277-026-07233-4
Vancouver
Longo E, Markovic U, Stella S, Antolino A, Massimino M, Fazio M, et al. Prolonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms. Annals of Hematology. 2026;105(12). doi:10.1007/s00277-026-07233-4
BibTeX
@article{Longo2026,
author = {Longo, Ermelinda and Markovic, Uros and Stella, Stefania and Antolino, Agostino and Massimino, Michele and Fazio, Manlio and Di Raimondo, Francesco and Allegra, Alessandro and Stagno, Fabio},
title = {Prolonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigms},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {12},
doi = {10.1007/s00277-026-07233-4}
}
EUVIMED